TY  - RPRT
TI  - MYBL2 drives prostate cancer plasticity and identifies CDK2 as a therapeutic vulnerability in RB1-loss and neuroendocrine prostate cancer
AU  - Ellis, L.
AU  - German, B.
AU  - Singh, J. N.
AU  - Burkhart, D. L.
AU  - Sheahan, A.
AU  - Bergom, H.
AU  - Morel, K. L.
AU  - Beltran, H.
AU  - Hwang, J.
AU  - Lawrenson, K.
PY  - 2024
DO  - 10.1101/2024.01.31.578216
UR  - https://www.biorxiv.org/content/10.1101/2024.01.31.578216v1
ID  - 10.1101/2024.01.31.578216
ER  -